SecSonar.com

Innoviva, Inc. (INVA)

Innoviva, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Innoviva, Inc. (INVA) is a Biotechnology company based in US with a market capitalization of $1.6B. Revenue grew 18.5% year-over-year and the company generated $195.8M in free cash flow. This page tracks INVA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 127 employees · IPO Oct 5, 2004

Valuation

Valuation & price

$21.97 · as of May 17, 2026 · -9.4% vs 52w high

6.9

P/E ratio

Latest-FY diluted EPS

1.36

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$24.24$20.45$16.67Jul 25Dec 25Jul 26Jul 7, 25$18.91Jul 9, 25$19.17Jul 11, 25$18.77Jul 15, 25$19.96Jul 17, 25$19.88Jul 21, 25$19.50Jul 23, 25$19.28Jul 25, 25$18.72Jul 29, 25$18.46Jul 31, 25$18.17Aug 4, 25$18.59Aug 6, 25$18.25Aug 11, 25$19.65Aug 13, 25$20.61Aug 15, 25$20.92Aug 19, 25$20.52Aug 21, 25$19.97Aug 25, 25$19.76Aug 27, 25$19.84Aug 29, 25$20.43Sep 3, 25$20.90Sep 5, 25$20.48Sep 9, 25$20.18Sep 11, 25$19.43Sep 16, 25$19.34Sep 18, 25$19.89Sep 22, 25$19.04Sep 24, 25$18.94Sep 26, 25$18.86Sep 30, 25$18.25Oct 2, 25$17.66Oct 6, 25$17.42Oct 8, 25$17.37Oct 10, 25$17.35Oct 14, 25$16.67Oct 16, 25$17.25Oct 21, 25$17.40Oct 23, 25$18.26Oct 27, 25$17.72Oct 29, 25$17.57Oct 31, 25$18.20Nov 4, 25$18.15Nov 6, 25$20.58Nov 10, 25$20.87Nov 12, 25$22.28Nov 14, 25$22.25Nov 18, 25$21.87Nov 20, 25$21.16Nov 25, 25$21.72Nov 28, 25$21.73Dec 2, 25$20.98Dec 4, 25$20.80Dec 8, 25$21.00Dec 10, 25$20.62Dec 12, 25$20.63Dec 16, 25$19.92Dec 18, 25$20.07Dec 22, 25$19.99Dec 24, 25$19.77Dec 29, 25$19.72Jan 2, 26$19.87Jan 6, 26$19.31Jan 8, 26$19.65Jan 12, 26$19.44Jan 14, 26$19.74Jan 16, 26$19.44Jan 21, 26$19.60Jan 23, 26$19.56Jan 27, 26$19.72Jan 29, 26$19.75Feb 2, 26$20.98Feb 4, 26$21.48Feb 9, 26$21.63Feb 11, 26$22.48Feb 13, 26$22.70Feb 18, 26$23.66Feb 20, 26$23.39Feb 24, 26$23.42Feb 26, 26$23.54Mar 2, 26$22.83Mar 4, 26$22.73Mar 6, 26$22.03Mar 10, 26$22.41Mar 12, 26$21.97Mar 17, 26$22.06Mar 19, 26$22.09Mar 23, 26$21.91Mar 25, 26$22.59Mar 27, 26$22.66Mar 31, 26$23.30Apr 2, 26$22.99Apr 7, 26$23.28Apr 9, 26$24.20Apr 13, 26$23.97Apr 15, 26$23.92Apr 17, 26$24.24Apr 22, 26$23.50Apr 24, 26$23.57Apr 28, 26$23.69Apr 30, 26$22.99May 4, 26$22.99May 6, 26$22.52May 8, 26$22.89May 12, 26$22.74May 14, 26$22.86May 18, 26$21.80May 20, 26$22.24May 22, 26$22.46May 28, 26$21.89Jun 1, 26$21.51Jun 3, 26$21.70Jun 5, 26$22.52Jun 9, 26$22.54Jun 11, 26$22.44Jun 15, 26$22.42Jun 17, 26$22.64Jun 22, 26$22.67Jun 24, 26$23.64Jun 26, 26$23.57Jul 2, 26$22.31
$16.6752-week range$24.24
Loading valuation history…

Fundamentals

Key fundamentals

$1.6B

Market cap

18.5%

Revenue growth (YoY)

72.3%

Gross margin

$195.8M

Free cash flow (USD)

-$281.9M

Net debt

Net cash position

7.4%

Share dilution

4/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$133.6MFY 2017$217.2MFY 2018$261.0MFY 2019$261.0MFY 2020$336.8MFY 2021$391.9MFY 2022$331.3MFY 2023$310.5MFY 2024$358.7MFY 2025$425.1M
$133.6M$425.1M

Free cash flow by year

2016 → 2025

FY 2016$60.7MFY 2017$141.7MFY 2018$223.5MFY 2019$257.4MFY 2020$313.1MFY 2021$362.5MFY 2022$201.7MFY 2023$140.7MFY 2024$188.4MFY 2025$195.8M
$60.7M$195.8M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 202295.8%FY 202386.3%FY 202489.8%FY 202572.3%
100.0%72.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventBoard Resignation and AppointmentMay 18, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 4, 2026Filing

Questions

Frequently asked questions

What is Innoviva, Inc.'s market cap?

Innoviva, Inc. (INVA) has a market capitalization of $1.6B.

What is INVA's P/E ratio?

INVA trades at a price-to-earnings ratio of 6.9, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is INVA's price-to-book (P/B) ratio?

INVA trades at 1.36 times book value per share.

Are insiders buying INVA stock?

SEC Form 4 filings show no open-market insider buys at Innoviva, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

RXRX

Recursion Pharmaceuticals, Inc.

$1.6B

NTLA

Intellia Therapeutics, Inc.

$1.6B

VIR

Vir Biotechnology, Inc.

$1.6B

VRDN

Viridian Therapeutics, Inc.

$1.6B

NRIX

Nurix Therapeutics, Inc.

$1.5B

NUVB

Nuvation Bio Inc.

$1.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.